New compounds were tested to evaluate their capacity of inhibiting BCR-ABL TK and HO-1 activities and their cytotoxicity in both NIL-resistant and -sensitive CML K562 cell lines. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.